Mylan, Pfizer Say Upjohn Deal Closing Delayed to 2nd Half
March 26 2020 - 7:40AM
Dow Jones News
By Colin Kellaher
Mylan N.V. and Pfizer Inc. on Thursday said they now expect
their planned deal to combine Pfizer's off-patent drugs business
Upjohn with generic drugmaker Mylan to close in the second half of
the year due the coronavirus pandemic.
The companies, which had expected the transaction to close in
mid-2020, said the pandemic has resulted in delays in the
regulatory review process.
The companies said Mylan will move its extraordinary general
meeting of shareholders, which had been slated for April 27 to
approve the transaction, to June 30, in conjunction with its annual
general meeting.
Mylan and Pfizer said there are no other changes to the terms or
plans regarding the transaction.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 26, 2020 07:25 ET (11:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Sep 2023 to Sep 2024